Bristol-Myers Squibb Co. announced new data from a cohort of the phase II CheckMate -142 trial evaluating Opdivo (nivolumab) and Yervoy (ipilimumab) for the treatment of patients with DNA mismatch repair deficient or microsatellite instability-high metastatic colorectal cancer.
Johns Hopkins Kimmel Cancer Center researchers developed a single blood test that screens for eight common cancer types and helps identify the location of the cancer.
A study published in the Journal of the National Cancer Institute indicates that screening the general population for mutations in specific genes is a more cost-effective way to detect people at risk and prevents more breast and ovarian cancers compared to only screening patients with a personal or family history of these diseases.
An international team, led by researchers at the University of California San Diego School of Medicine, has developed a genetic tool for predicting age of onset of aggressive prostate cancer.
Exelixis Inc. and Ipsen announced detailed results of the pivotal phase III CELESTIAL trial in patients with previously treated advanced hepatocellular carcinoma, which will be presented in a late-breaking oral session at the 2018 ASCO-GI Symposium.
Specialty diagnostics company Precipio Inc. announced preliminary data from an ongoing study on the impact of academic pathology expertise on diagnostic accuracy.
Researchers at UT Southwestern's Simmons Cancer Center have shown that RAS molecules act in pairs, known as dimers, to cause cancer, findings that could help guide them to a treatment.
Scientists from The Scripps Research Institute discovered two estrogen-mimicking compounds found in many foods appear to potently reverse the effects of palbociclib/letrozole, a popular drug combination for treating breast cancer.
Certain head and neck cancers that are positive for high-risk types of human papillomavirus have a better prognosis and may need less aggressive treatment.
The study, “Axicagagene Ciloleucel (CD19 CAR T) in Refractory Large B-Cell Lymphoma,” was led by Sattva Neelapu of the MD Anderson Cancer Center and Frederick Locke of the H. Lee Moffitt Cancer Center and Research Institute.
